Your browser doesn't support javascript.
loading
Increasing emergency department attendances in central London with methamphetamine toxicity and associated harms.
Harnett, James T; Dargan, Paul I; Dines, Alison M; Archer, John R H; Greene, Shaun L; Hunter, Laura J; Wood, David M.
Afiliação
  • Harnett JT; Emergency Department, University College London Hospitals NHS Foundation Trust, London, UK j.harnett@nhs.net.
  • Dargan PI; Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Dines AM; 'Faculty of Life Sciences and Medicine, King's College, London, UK.
  • Archer JRH; Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Greene SL; Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Hunter LJ; 'Faculty of Life Sciences and Medicine, King's College, London, UK.
  • Wood DM; Victorian Poisons Information Centre, Austin Hospital, Melbourne, Victoria, Australia.
Emerg Med J ; 39(6): 463-466, 2022 Jun.
Article em En | MEDLINE | ID: mdl-34649939
BACKGROUND: Methamphetamine is a stimulant drug of abuse with increasing prevalence of use worldwide leading to public health concern. While previous research by our group a decade ago found no evidence of increasing harms associated with methamphetamine use in the UK, there are conflicting data on whether or not this is still the case. This paper aims to identify trends in methamphetamine-related harms and characterise the clinical features of ED presentations involving methamphetamine with gamma-hydroxybutyrate/gamma-butyrolactone (GHB/GBL). METHODS: We retrospectively interrogated a database of all toxicology-related presentations to two central London EDs, extracting data on drugs involved for presentations relating to methamphetamine between 2005 and 2018 to enable analysis of trends. Further clinical data were extracted for presentations between 2014 and 2018 to give a 4-year case series. RESULTS: A total of 1244 presentations involving the use of methamphetamine were identified. The number of presentations rose from 4 in 2005 (1.9% of all recreational drug presentations) to 294 (16.2%) in 2018. A total of 850 cases were identified for the 2014-2018 case series, 94.9% were male with a median (range) age of 35.1 (16-67) years. The most common clinical features in the methamphetamine presentations were neuropsychiatric: agitation (41.5%), anxiety (35.2%), hallucinations (16.5%) and psychosis (14.8%). GHB/GBL was co-used in 54.2% of presentations and appeared to attenuate the neuropsychiatric features seen. Use of GHB/GBL was associated with a higher Poisoning Severity Score and requirement for level 2/3 (high dependency unit/intensive care unit (ICU)) care. CONCLUSION: ED attendances in central London relating to methamphetamine use have risen over the last decade. Combining methamphetamine with GHB/GBL is common and is associated with a higher Poisoning Severity Score and need for ICU level care. Further work is required to establish whether further resources need to be directed at this clinical and public health problem.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oxibato de Sódio / Metanfetamina Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oxibato de Sódio / Metanfetamina Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article